S&P Futures
4,140.50 -6.25 (-0.15%) Dow Futures
32,725.00 -32.00 (-0.10%) Nasdaq Futures
13,220.00 -8.75 (-0.07%) Russell 2000 Futures
1,919.10 -2.70 (-0.14%) Crude Oil
89.31 +0.30 (+0.34%) Gold
1,787.90 -3.30 (-0.18%)
Gamida Cell Ltd. (GMDA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.9500 |
| Open | 1.9200 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1400 |
| Day's Range | 1.9200 - 2.2197 |
| 52 Week Range | 1.4800 - 5.9100 |
| Volume | |
| Avg. Volume | 356,103 |
| Market Cap | 129.567M |
| Beta (5Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5310 |
| Earnings Date | May 10, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.40 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GMDA
Related Research
- Gamida Cell Ltd.Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.RatingFair ValueEconomic Moat4 days agoMorningstar
- Simply Wall St.
How Many Gamida Cell Ltd. (NASDAQ:GMDA) Shares Do Institutions Own?
The big shareholder groups in Gamida Cell Ltd. ( NASDAQ:GMDA ) have power over the company. Large companies usually...
- Business Wire
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
BOSTON, August 01, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. Omidubicel is a first-in-class, ad
- Business Wire
Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
BOSTON, June 13, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the JMP Securities Life Sciences Conference, June 16, 2022 with a presentation at 2:00 p.m. ET in New York, NY.
